

UCLA

UCLA Previously Published Works

Title

Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States

Permalink

<https://escholarship.org/uc/item/2kf9s474>

Journal

Clinical Infectious Diseases, 76(3)

ISSN

1058-4838

Authors

Tenforde, Mark W
Self, Wesley H
Zhu, Yuwei
[et al.](#)

Publication Date

2023-02-08

DOI

10.1093/cid/ciac381

Peer reviewed

1 Washington, USA; ¹²Baystate Medical Center, Springfield, Massachusetts, USA; ¹³Intermountain Medical
2 Center and University of Utah, Salt Lake City, Utah, USA; ¹⁴University of Michigan School of Public
3 Health, Ann Arbor, Michigan, USA; ¹⁵Oregon Health & Science University Hospital, Portland, Oregon,
4 USA; ¹⁶Emory University School of Medicine, Atlanta, Georgia, USA; ¹⁷Cleveland Clinic, Cleveland, Ohio,
5 USA; ¹⁸Stanford University School of Medicine, Palo Alto, California, USA; ¹⁹Ronald Reagan-UCLA Medical
6 Center, Los Angeles, California, USA; ²⁰University of Miami, Miami, Florida, USA; ²¹Washington
7 University, St. Louis, Missouri, USA; ²²Ohio State University Wexner Medical Center, Columbus, Ohio,
8 USA; ²³University of Michigan School of Medicine, Ann Arbor, Michigan, USA; ²⁴Beth Israel Deaconess
9 Medical Center, Boston, Massachusetts, USA.

10

11 **Corresponding Author:**

12 Mark W. Tenforde, MD, PhD; Centers for Disease Control and Prevention; 1600 Clifton Road NE, H24-7,
13 Atlanta, Georgia, USA 30329-4027. Email: mtenforde@cdc.gov; phone: 404-861-0404.

14

15

16 **Alternative Corresponding Author:**

17 Wesley H. Self, MD, MPH; Vanderbilt University Medical Center; 1313 21st Avenue South, 312 Oxford
18 House, Nashville, Tennessee, USA 37232. Email: wesley.self@vumc.org; phone: 615-936-8047.

19 **Short Title:** COVID-19 vaccine effectiveness over time

1 **ABSTRACT**

2 **Background:** COVID-19 mRNA vaccines were authorized in the United States in December 2020.

3 Although vaccine effectiveness (VE) against mild infection declines markedly after several months,
4 limited understanding exists on the long-term durability of protection against COVID-19-associated
5 hospitalization.

6 **Methods:** Case control analysis of adults (≥ 18 years) hospitalized at 21 hospitals in 18 states March 11 –
7 December 15, 2021, including COVID-19 case patients and RT-PCR-negative controls. We included adults
8 who were unvaccinated or vaccinated with two doses of a mRNA vaccine before the date of illness
9 onset. VE over time was assessed using logistic regression comparing odds of vaccination in cases versus
10 controls, adjusting for confounders. Models included dichotomous time (< 180 vs ≥ 180 days since dose
11 two) and continuous time modeled using restricted cubic splines.

12 **Results:** 10,078 patients were included, 4906 cases (23% vaccinated) and 5172 controls (62%
13 vaccinated). Median age was 60 years (IQR 46–70), 56% were non-Hispanic White, and 81% had ≥ 1
14 medical condition. Among immunocompetent adults, VE < 180 days was 90% (95%CI: 88–91) vs 82%
15 (95%CI: 79–85) at ≥ 180 days ($p < 0.001$). VE declined for Pfizer-BioNTech (88% to 79%, $p < 0.001$) and
16 Moderna (93% to 87%, $p < 0.001$) products, for younger adults (18-64 years) [91% to 87%, $p = 0.005$], and
17 for adults ≥ 65 years of age (87% to 78%, $p < 0.001$). In models using restricted cubic splines, similar
18 changes were observed.

19 **Conclusion:** In a period largely pre-dating Omicron variant circulation, effectiveness of two mRNA doses
20 against COVID-19-associated hospitalization was largely sustained through 9 months.

21 **Key Words:**

22 COVID-19; duration of protection; waning; vaccine effectiveness; mRNA

1 INTRODUCTION

2 The Coronavirus Disease 2019 (COVID-19) pandemic led to an estimated 5.4 million deaths worldwide
3 through December 2021 [1]. Highly effective vaccines are available, and vaccination is the best tool to
4 control the impact of the pandemic [2, 3]. In the United States, three licensed vaccines are available,
5 with most vaccinated persons receiving messenger RNA (mRNA) COVID-19 vaccine products including
6 mRNA-1273 (from Moderna) and BNT162b2 (from Pfizer-BioNTech) [4]. Vaccination has reduced the
7 burden of COVID-19 including COVID-19-associated deaths in the U.S. [5, 6], with most severe COVID-19
8 illnesses and deaths occurring among unvaccinated persons [7, 8].

9 In countries with higher vaccination coverage, reductions in vaccine effectiveness (VE) with passage of
10 time prompted booster recommendations for COVID-19 vaccines [9]. In these vaccinated populations,
11 surges of COVID-19 complicate the understanding of the protective effect of vaccines and policy
12 discussions for several reasons. First, with increasing time since vaccination, protection has varied by
13 disease severity, with more sustained vaccine protection against severe disease as compared with mild
14 infections [10, 11]. These infections in vaccinated individuals could be due to waning of antibodies [12,
15 13], particularly in the mucosal compartments at the site of infection, or from emergence of SARS-CoV-2
16 variants that might escape immune protection. In contrast, durable memory B cell and T cell responses
17 might provide sustained protection against more severe disease [14], possibly including heterotypic
18 protection against new variants. Second, protection may differ by underlying conditions such as
19 immunosuppression [15], vaccine product [16, 17], and number of doses received [18]. Thus, as the
20 pandemic continues to evolve, disentangling factors of waning immunity, viral evasion of immunity,
21 number of doses and type of vaccine, and host immune responses have become increasingly complex.
22 Ongoing real-world VE studies in large, diverse populations can inform vaccination program goals in
23 terms of understanding of protection provided for different levels of disease severity, populations in

1 whom booster doses may be most beneficial for the prevention of severe outcomes and timing of
2 booster doses, and the need for potential antigen updates in vaccines.

3 The Centers for Disease Control and Prevention (CDC) collaborates with the Influenza and Other Viruses
4 in the Acutely Ill (IVY) Network to monitor the effectiveness of vaccines for the prevention of COVID-19-
5 associated hospitalizations among U.S. adults [3, 16]. In this report, we evaluate the duration of 2-dose
6 mRNA vaccine protection against COVID-19 hospitalizations during the first year of the U.S. vaccination
7 program. Our primary goal was to examine VE over time by host factors such as age and underlying
8 conditions, vaccine product, and immunosuppression status to evaluate the durability of vaccine
9 protection to inform future vaccine strategies.

10 **METHODS**

11 We monitor the effectiveness of COVID-19 vaccines for the prevention of COVID-19 hospitalization
12 among U.S. adults (≥ 18 years of age) by enrolling adults at 21 U.S. medical centers. We assessed the
13 effectiveness of the mRNA vaccines over time in patients admitted March 11 through December 15,
14 2021 using a case-control design. Interim durability estimates including IVY Network enrollments
15 through July 14, 2021 were previously published (including 3089 hospitalized adults, with a median of 65
16 days between receipt of dose 2 and illness onset among vaccinated patients) [19]; this analysis adds five
17 additional months of enrollment data including a longer duration of follow-up since vaccination during a
18 period when the SARS-CoV-2 Delta variant predominated.

19 We considered immunocompetent and immunocompromised patients separately because of variation
20 in immune responses to COVID-19 vaccination in these patients.[15]. Immunocompromising conditions
21 were defined as having one or more of the following: active solid organ cancer (defined as treatment for
22 the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer, HIV infection
23 with or without AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid

1 organ transplant, active immunosuppressive medication use, systemic lupus erythematosus, rheumatoid
2 arthritis, psoriasis, scleroderma, or inflammatory bowel disease. Enrollment methods have previously
3 been described [3, 7]. In brief, COVID-19 case patients had COVID-19-like illness (CLI) and tested positive
4 for SAR-CoV-2 by molecular or antigen test within 10 days of illness onset. Two control groups of
5 hospitalized adults without COVID-19 were included: (1) a “test-negative” control group comprised of
6 patients hospitalized with CLI who tested negative for SARS-CoV-2 by reverse transcription polymerase
7 chain reaction (RT-PCR) and (2) a “syndrome-negative” control group comprised of patients hospitalized
8 without CLI who tested negative for SARS-CoV-2 by RT-PCR. VE using individual control groups was
9 highly similar, and therefore patients from both groups were combined into a single control group. Case
10 or control status was determined using SARS-CoV-2 clinical testing results and results from central RT-
11 PCR testing of upper respiratory specimens collected at enrollment and tested at Vanderbilt University
12 Medical Center (Nashville, Tennessee). Patients enrolled as test-negative controls who subsequently
13 tested positive for SARS-CoV-2 were reassigned as a COVID-19 case-patient and syndrome-negative
14 controls with a subsequent positive SARS-CoV-2 test were excluded from the analysis.

15 COVID-19 vaccination status and vaccine product information were determined through self-report
16 during enrollment interviews with patients or their proxies and systematic review of source
17 documentation including hospital electronic medical records, state vaccine registry searches, and
18 vaccination record cards. Patients were considered vaccinated for this analysis if two doses of a single
19 mRNA vaccine product were documented or self-reported (with date and location) ≥ 14 days before a
20 reference date, defined as the date of symptom onset for cases and test-negative controls or five days
21 prior to hospital admission for syndrome-negative controls. If no COVID-19 vaccine was received prior to
22 the reference date, patients were considered unvaccinated. Patients who received 1 or more doses of a
23 mRNA vaccine but did not meet study criteria for full vaccination, who received mixed vaccine products,

1 or who received a non-mRNA vaccine were excluded, as well as patients who received more than two
2 doses of a mRNA vaccine with the third dose received ≥ 7 days before illness onset.

3 Patients were classified as being in a period of higher proportions of lineages other than Delta (pre-
4 Delta) period if their admission date was before July 1st 2021 [4]. Otherwise, patients with an admission
5 date on or after July 1st, 2021 were classified as being in a period of higher B.1.617.2 and AY lineages
6 (Delta period). Information on patients' age, sex, self-reported race and ethnicity, and preexisting
7 chronic medical conditions were obtained through electronic medical record review and structured
8 enrollment interviews.

9 Logistic regression models were used to estimate VE by time since vaccination with different models
10 treating time as binary (<180 days vs ≥ 180 days between second dose and reference date) and as
11 continuous (applied a restricted cubic spline with number of knots determined by the lowest AIC of the
12 regression model tested with 3-7 knots). Briefly, we applied a spline to the daily time term due to the
13 non-linear nature of VE over time; in other words, the use of splines allowed the waning speed to
14 change over time opposed to a constant decline. Each logistic regression model used COVID-19 case
15 status as the outcome and vaccination status (vaccinated vs unvaccinated) as the predictor along with
16 the time since vaccination term (binary or continuous). Models included additional covariates for
17 calendar date of admission (in biweekly intervals), age (continuous years), sex, self-reported race and
18 ethnicity, presence of underlying chronic conditions, immunocompromised status, and US Health and
19 Human Services region of the admitting hospital. Unvaccinated patients were assigned a reference value
20 of zero days since vaccination. In binary time models, VE was estimated using logistic regression
21 comparing odds of case vs control outcome by a primary predictor of vaccination status (vaccinated
22 <180 days before symptom onset, vaccinated ≥ 180 days since symptom onset, or unvaccinated), using
23 the equation $VE = (1 - aOR) \times 100$. In continuous time models, VE was calculated at each time since
24 vaccination t as $VE(t) = (1 - aOR(t)) \times 100$, where $aOR(t)$ is the estimated odds ratio of being a case

1 patient for vaccinated patients at t days since vaccination compared to an unvaccinated patient at 0
2 days adjusted for the specified covariates. 95% confidence intervals (CI) for these VE curves were
3 obtained using bootstrapping with 1000 replicates. Interaction terms were introduced to evaluate VE
4 over time stratified by characteristics of interests including age group (18–64 years or ≥ 65 years),
5 underlying chronic medical conditions (0 vs ≥ 1), vaccine product received (Pfizer BioNTech vs Moderna),
6 and baseline immunocompromising conditions. An additional model limited to patients with admission
7 date on or after July 1st, 2021 was conducted to estimate VE over the Delta period. Separate models
8 were constructed for immunocompetent and immunosuppressed participants due to known effect
9 modification of VE by immune function status [15].

10 VE across binary time since vaccination groups was compared with likelihood ratio chi-squared tests. P-
11 values < 0.05 were considered statistically significant. This activity was conducted as a public health
12 surveillance activity, with waiver of informed consent.

13 RESULTS

14 Of 12,513 patients enrolled through December 15, 2021, 2435 were excluded (1312 who were not
15 vaccinated with 2 doses of a mRNA vaccine or received a third dose; 606 who received a non-mRNA
16 vaccine or mixed products; and 517 who met other exclusion criteria). Of 10,078 patients included in the
17 analysis, 4906 (49%) were COVID-19 case patients and 5172 (51%) were COVID-19-negative controls
18 (Table 1). Among 4906 cases, 1119 (23%) were vaccinated and, among 5172 controls, 3229 (62%) were
19 vaccinated. Overall, median age was 60 years (IQR: 46 – 70), 5675 (56%) were non-Hispanic White, 2198
20 (22%) non-Hispanic Black, and 1589 (16%) Hispanic of any race, 8203 (81%) had one or more chronic
21 medical conditions, and 1940 (19%) had an immunocompromising condition. COVID-19 case patients
22 were younger on average than controls (median 57 vs 62 years; $p < 0.001$), were less likely to report
23 having prior laboratory confirmed infection with SARS-CoV-2 (3% vs 9%; $p < 0.001$), and, among those

1 who were vaccinated, had a longer median time since receiving the second vaccine dose (median 163 vs
2 127 days, $p < 0.001$). Among 4862 (99%) COVID-19 case-patients with hospital outcomes, 538 (11%) died
3 within 28 days of admission, 1919 (39%) were admitted to the intensive care unit, and the median
4 length of stay among those who survived and were discharged by day 28 ($n = 3782$) was 6 (IQR 3 – 10)
5 days.

6 Overall, adjusted VE among patients with immunocompromising conditions was 63% [95% CI: 55 – 69],
7 and decreased from < 180 days (65% [95%CI: 57 – 72]) to ≥ 180 days (53% [95%CI: 38 – 65]) after vaccine
8 dose two ($p = 0.04$) [Figure 1]. VE among immunocompetent individuals decreased between < 180 days
9 (90% [95% CI: 88 – 91]) at a median of 108 days (interquartile range [IQR]: 65-143) and ≥ 180 days (82%
10 [95% CI: 79 – 85]) at a median of 215 days (IQR: 197-240) after the second vaccine dose ($p < 0.001$).

11 Restricting to the period of predominant SARS-CoV-2 Delta circulation, accounting for 72% of patient
12 enrollments, results were largely similar with an estimated VE of 90% [95%CI: 88 – 91] at < 180 days
13 versus 83% [95%CI: 80 – 86] at ≥ 180 days ($p < 0.001$). Among immunocompetent adults, VE was higher at
14 < 180 days compared to ≥ 180 days across multiple subgroups (all $p < 0.05$), including adults aged 18-64
15 years (91% [95%CI: 90 – 93] vs 87% [95%CI: 83 – 90]; $p = 0.005$); adults ≥ 65 years of age (87% [95%CI: 84
16 – 89] vs 78% [95%CI: 72 – 82]; $p < 0.001$); the Pfizer-BioNTech product (88% [95%CI: 86 – 90] vs 79%
17 [95%CI: 74 – 83]; $p < 0.001$); the Moderna product (93% [95%CI: 91 – 94] vs 87% [95%CI: 83 – 90];
18 $p < 0.001$); those with no underlying chronic medical conditions (97% [95%CI: 96 – 98] vs 90% [95%CI: 84
19 – 94]; $p < 0.001$); and those with ≥ 1 underlying condition (88% [95%CI: 86 – 89] vs 80% [95%CI: 76 – 84];
20 $p < 0.001$) [Figure 1].

21 Next, we looked at VE over continuous time. The continuous time since vaccination models performed
22 best, based on the lowest AIC of the overall model, using a restricted cubic spline term with 5 knots.

23 Standard quantiles for the cubic spline for time since vaccination of 0.05, 0.275, 0.50, 0.775, and 0.95 (at
24 31, 91, 140, 187, and 253 days since vaccination) were used. In immunocompetent patients, VE was 90%

1 initially (at 14 days since vaccination), increased to a maximum of 93% after 75 days, and then
2 decreased to 80% after 270 days (Figure 2), with time since vaccination being a significant factor in
3 estimating VE ($p < 0.001$). Among immunocompetent adults, VE estimates similarly varied by time within
4 subgroups of interest. For the Pfizer-BioNTech vaccine, VE peaked at 92% after 74 days and decreased to
5 75% at 270 days, and for the Moderna product VE peaked at 94% after 83 days and decreased to 86%
6 after 270 days [Figure 3], with time from vaccination being significant in each group ($p < 0.001$). For those
7 aged 18-64, VE peaked at 94% after 84 days and decreased to a minimum of 86% at 198 days, and for
8 those 65 or older VE peaked at 92% initially at 14 days and decreased to 73% after 270 days [Figure 4],
9 with time from vaccination being significant in each group ($p < 0.001$). Models testing additional
10 interactions also showed a change in VE over time for both the group with no underlying conditions and
11 those with ≥ 1 underlying condition (Supplementary Figure 1) and for those in the Delta period
12 (Supplementary Figure 2). Immunosuppressed individuals showed overall lower VE compared to
13 immunocompetent patients over time (Supplementary Figure 3).

14 **DISCUSSION**

15 In this multicenter evaluation across 18 states over the first year following COVID-19 vaccine
16 introduction, we found that vaccination with two doses of an mRNA product provided protection against
17 COVID-19 hospitalization prior to predominant Omicron variant and subvariant circulation. Effectiveness
18 was generally sustained at $\geq 80\%$ over a period of 270 days with some gradual decline after peaking 2-3
19 months after the second vaccine dose. This pattern of protection was similar across subgroups, such as
20 by vaccine product. Notably, overall protection was lower for older adults (≥ 65 years of age) compared
21 to young adults (18-64 years of age) and was modestly lower after 180 days (87% vs 78%), highlighting
22 the importance of additional vaccine doses in older adults who are at increased risk of severe COVID-19
23 illness. Both mRNA vaccine products provided a high level of protection, with modestly higher VE
24 observed for the Moderna compared to the Pfizer-BioNTech vaccine [16, 17]

1 Findings from our analysis are consistent with published studies that have shown consistently high and
2 generally sustained protection from COVID-19 mRNA vaccines against severe outcomes [7, 10]. Almost
3 three-quarters of COVID-19 cases occurred during a period in which the SARS-CoV-2 Delta variant
4 accounted for most infections in the U.S. However, the surveillance period pre-dated more recent
5 circulation of the SARS-CoV-2 Omicron variant, which has greater immune escape corresponding with
6 lower vaccine protection [20, 21]. In contrast to protection against severe disease, studies show that
7 protection against milder infection decreases faster with time since vaccination [10]. This could be
8 related to waning antibodies or escape from neutralizing antibody protection for new SARS-CoV-2
9 variants that circulated after mRNA vaccine introduction [22]. Varied protection by outcome is
10 consistent with the nature of immunity against respiratory infections, including influenza [23]. With
11 respiratory infections, mechanisms of immunity are complex and involve mucosal and humoral
12 compartments [23]. Immunity can be time-varying with shorter duration of protection at the mucosal
13 surfaces, which might lead to breakthrough infections after primary infection or vaccination. However,
14 recall of memory responses can prevent severe disease, or attenuate severe disease in immunized
15 persons with breakthrough infections.

16 Our findings might contribute to future discussions around goals of the COVID-19 vaccination program
17 and booster doses, especially as recurrent surges in infections continue to occur either due to declining
18 immunity or emergence of variants that escape immunity, such as Omicron [24]. Recommendations for
19 additional COVID-19 vaccine doses have been implemented in several countries [25, 26]. These decisions
20 were initially driven by findings of suboptimal protection in immunosuppressed persons and declining
21 protection against mild to moderate infection over time or with emerging variants. Recent increases in
22 SARS-CoV-2 incidence were caused almost exclusively by the Omicron variant and subvariants which
23 evade vaccine-associated immunity to a greater extent than prior circulating variants [21, 27]. Although
24 additional vaccine doses diversify protection against more divergent variants from the ancestral strain

1 (WA1/2020) targeted by current vaccines, these benefits may be relatively short-lived compared to
2 conserved protection we observed against previously circulating variants [26, 28]. Strategies used for
3 influenza vaccination, including international surveillance with antigenic and genetic characterization of
4 viruses and/or forecasting coupled with periodic updates in vaccine antigens and/or multivalent
5 vaccines, may be a long-term strategy to durably reduce the impact of severe COVID-19 as SARS-CoV-2
6 continues to circulate globally. However, challenges remain in predicting new SARS-CoV-2 variants.

7 Our report has several limitations. We focused on hospitalized outcomes only. We did not include adults
8 who received more than 2 doses of an mRNA vaccine, first recommended for individuals with
9 immunocompromising conditions in August 2021 [29] and in the general adult population in November
10 2021 [9]. We did not include adults who received mixed vaccine products due to a limited number of
11 patients with heterologous vaccination. These data predated more recent predominance of the SARS-
12 CoV-2 Omicron variant. We also could not control for some potential time-varying confounders such as
13 varying force of infection due to factors such as changes in mitigation measures. Although this analysis
14 included hospitalized adults from 18 geographically and demographically diverse states, patients may
15 not have been fully representative of the US adult population. In models evaluating patients with
16 immunocompromising conditions, diverse immunocompromising conditions associated with variable
17 degrees of immunosuppression and potentially with durability of vaccine protection were combined.
18 Lastly, a high proportion of these hospitalized adults had multiple chronic medical conditions, thus
19 reducing the generalizability to other populations with lower burden of chronic medical conditions.

20 **Conclusions**

21 In this multi-center US study, we found high and largely sustained protection against COVID-19 following
22 receipt of two doses of mRNA vaccine in medically complex hospitalized patients. These findings
23 reinforce that even with increasing infections in vaccinated populations, vaccination continued to

1 provide sustained protection against severe COVID-19 resulting in hospitalization. With recurrent surges
2 in infection and emergence of SARS-CoV-2 variants with greater immune evasion [20, 30], ongoing
3 monitoring of VE in hospitalized patients can inform prioritizing certain populations with additional
4 vaccine doses or development of vaccines with updated antigens.

5 **Notes:**

6 **Disclaimer**

7 The findings and conclusions in this report are those of the authors and do not necessarily represent the
8 official position of the Centers for Disease Control and Prevention.

9 **Funding**

10 This work was supported by the United States Centers for Disease Control and Prevention (CDC).

11 **Conflicts of Interest**

12 All authors have completed and submitted the International Committee of Medical Journal Editors form
13 for disclosure of potential conflicts of interest. Wesley H. Self reports grant funding from CDC for this
14 work, grants and consultant fees from Merck (for research on the surveillance of pneumococcal
15 infections) and Gilead Sciences (for research on the surveillance of hepatitis C virus infections) outside
16 this work. Manjusha Gaglani reports grant support from CDC (Ambulatory US Flu/COVID VE Network and
17 Adult Inpatient Flu/COVID VE Network, HAIVEN), CDC-Abt Associates (Flu Vax Immunogenitiy RCT and
18 RECVOERPROTECT COVID/Flu VE studies), CDC-Westat (VISION COVID Study), and Janssen (Johnson &
19 Johnson) (RSV Severity App Birth Cohort Study). Adit A. Ginde reports grant support from CDC, National
20 Institute of Health (NIH), Department of Defense (DoD), AbbVie, and Faron Pharmaceuticals. Jonathan
21 D. Casey reports grants from the CDC, NIH (K23HL153584), and Department of Defense. Nicholas Mohr
22 reports grants from the CDC (funded 2 other multicenter COVID-related projects separate from this
23 work through payments to my institution). Tresa McNeal reports a grant from CDC and fees from the
24 Society of Hospital Medicine for a talk about managing CHF patients. Kevin Gibbs reports grants from
25 the CDC and the received grant funding for participation in executive committee of COVID-19
26 therapeutics from the NIH (ACTIV-4HT NECTAR Trial). D. Clark Files reports grant support from CDC,

1 consultant fees from Cytovale and membership on a Medpace Data Safety Monitoring Board (DSMB).
2 David N. Hager reports contracts from CDC, NHLBI (funding for participation in the ACTIV4d – Host
3 Tissue Trial) and Incyte Corporation (funding to enroll in RUCOVID-DEVENT) and membership on the
4 SAFE EVICT Trial of VIT C in COVID-19 as DSMB chair. Matthew C. Exline reports talks on nutrition in
5 COVID pneumonia at the American Society of Parenteral and Enteral Nutrition (ASPEN) conference
6 sponsored by Abbott Labs. Michelle N. Gong reports grant support from CDC, NHLBI, NIH, and Agency
7 for Healthcare Research and Quality (AHRQ), travel support for American Thoracic Society board
8 meeting, and membership on the Regeneron DSMB for monoclonal antibodies in COVID-19. Nicholas
9 Johnson reports grants from CDC, NIH/NHLBI/NINDS, and University of Washington Royalty Research
10 Fund, and payment for expert testimony from the Washington Department of Health. Ithan D. Peltan
11 reports grants from CDC, NIH, Intermountain Research & Medical Foundation, and Janssen
12 Pharmaceuticals, and institutional fees from Asahi Kasei Pharma and from Regeneron Pharmaceuticals.
13 Samuel M. Brown reports grants from CDC, NIH (for trials and other research activities related to
14 COVID), and Department of Defense (to study COVID); fees from Hamilton ventilators for chairing a
15 DSMB; and personal fees from New York University for service on a DSMB. Emily T. Martin reports a
16 grant from Merck outside the submitted work. Arnold Monto reports grant support from CDC, NIH,
17 NIAID, and membership on a DSMB for the Food and Drug Administration (FDA). Akram Khan reports
18 grants from CDC, Gilead Sciences, Ely Lilly, United Therapeutics, BOA-Medical and 4D Medical and
19 membership on the Guidelines Committee for Chest. Catherine L. Hough reports grants from CDC, NIH,
20 and the American Lung Association. Abhijit Duggal reports a grant from the CDC and consulting fees
21 from ALung Technologies (Steering Committee). Jennifer Wilson reports grants from the CDC and NIH
22 (ARREST Pneumonia Trial UH3HL141722, ACTIV3a and 3b trials, and ACTIV4a trial), and membership on
23 the American Board of Internal Medicine Critical Care Medicine exam committee. Steven Y. Chang
24 reports grants from CDC and Regeneron (for 6R88-COV-2040 trial) and consulting fees from PureTech

1 Health (for COVID study) and Kiniska (for possible ARDS study). Jennie H. Kwon reports grant support
2 from CDC and NIH (1K23 AI137321-01A1). Adam S. Luring reports grants from the CDC, NIH, and
3 Burroughs Wellcome Fund, consultant fees for antiviral drugs from Sanofi and fees from Roche for
4 membership on a baloxavir trial steering committee. Natasha Halasa reports grants from CDC, NIH,
5 Sanofi and Quidel and honoraria for speaking at a continuing medical education event at American
6 Academy of Pediatrics. Carlos G. Grijalva reports consultant fees from Pfizer, Merck, and Sanofi and
7 grants from Syneos Health, CDC, NIH, FDA, AHRQ, and Sanofi. Todd Rice reports grants from CDC and
8 Abbvie Inc, consultant fees from Cytovale, Inc. and Cumberland Pharmaceuticals Inc., membership on a
9 Sanofi, Inc. DSMB, a voluntary role as the Immediate Past President of ASPEN and stock in Cumberland
10 Pharmaceuticals, Inc. Ian Jones reports grants/contracts from the CDC, NIH, Quidel, and Sanofi.
11 Christopher J. Lindsell reports grants/contracts from CDC, NIH, DoD, bioMerieux, Endpoint Health,
12 Entegron, Inc., and AbbVie; a patent issued to Cincinnati Children's Hospital Medical Center for risk
13 stratification in sepsis and septic shock, membership on a Study Principal Investigators DSMB for clinical
14 trials unrelated to the current work, Executive Committee; Immediate Past President, Member, Board of
15 Directors, Association for Clinical and Translational Science, and stock options in Bioscape Digita
16 unrelated to the current work. William B. Stubblefield reports a grant from the CDC and NIH
17 (5K12HL133117-05). No other potential conflicts of interest were disclosed.

1 References

- 2 1. World Health Organization. WHO coronavirus (COVID-19) dashboard. Available
3 at: <https://covid19.who.int/>. Accessed on: 4 Jan 2022.
- 4 2. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of
5 BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among
6 Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S.
7 Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(13): 495-500.
- 8 3. Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for
9 Preventing Covid-19 Hospitalizations in the United States. *Clin Infect Dis* **2021**.
- 10 4. Centers for Disease Control and Prevention. CDC COVID Data Tracker. Available at:
11 https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days. Accessed on: 4 Jan
12 2022.
- 13 5. Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations Against COVID-19 May
14 Have Averted Up To 140,000 Deaths In The United States. *Health Aff (Millwood)* **2021**; 40(9):
15 1465-72.
- 16 6. McNamara LA, Wiegand RE, Burke RM, et al. Estimating the early impact of the US COVID-19
17 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions,
18 and deaths among adults aged 65 years and older: an ecological analysis of national surveillance
19 data. *Lancet* **2021**.
- 20 7. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19
21 Hospitalization and Disease Severity. *JAMA* **2021**; 326(20): 2043-54.
- 22 8. Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases,
23 Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021.
24 *MMWR Morb Mortal Wkly Rep* **2021**; 70(37): 1284-90.
- 25 9. US Food & Drug Administration. Coronavirus (COVID-19) update: FDA expands eligibility for
26 COVID-19 vaccine boosters. Available at: [fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters)
27 [announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters).
28 Accessed on: 4 Jan 2022.
- 29 10. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6
30 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet*
31 **2021**; 398(10309): 1407-16.
- 32 11. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-
33 CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
34 *Lancet* **2022**.
- 35 12. Patel MM, Thornburg NJ, Stubblefield WB, et al. Change in Antibodies to SARS-CoV-2 Over 60
36 Days Among Health Care Personnel in Nashville, Tennessee. *JAMA* **2020**.
- 37 13. Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19
38 Vaccine over 6 Months. *N Engl J Med* **2021**; 385(24): e84.
- 39 14. Guerrero G, Picozza M, D'Orso S, et al. BNT162b2 vaccination induces durable SARS-CoV-2-
40 specific T cells with a stem cell memory phenotype. *Sci Immunol* **2021**; 6(66): eabl5344.
- 41 15. Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19
42 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults -
43 Nine States, January-September 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(44): 1553-9.
- 44 16. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-
45 BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations
46 Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
47 *MMWR Morb Mortal Wkly Rep* **2021**; 70(38): 1337-43.

- 1 17. Dickerman BA, Gerlovin H, Madenci AL, et al. Comparative Effectiveness of BNT162b2 and
2 mRNA-1273 Vaccines in U.S. Veterans. *N Engl J Med* **2021**.
- 3 18. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19
4 vaccine for preventing severe outcomes in Israel: an observational study. *Lancet* **2021**;
5 398(10316): 2093-100.
- 6 19. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and
7 Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States,
8 March-July 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(34): 1156-62.
- 9 20. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2
10 Omicron Infection. *N Engl J Med* **2021**.
- 11 21. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma Neutralization of the SARS-CoV-2 Omicron
12 Variant. *N Engl J Med* **2022**; 386(6): 599-601.
- 13 22. Cromer D, Juno JA, Houry D, et al. Prospects for durable immune control of SARS-CoV-2 and
14 prevention of reinfection. *Nat Rev Immunol* **2021**; 21(6): 395-404.
- 15 23. Patel MM, York IA, Monto AS, Thompson MG, Fry AM. Immune-mediated Attenuation of
16 Influenza Illness after Infection: Opportunities and Challenges. *Lancet Microbe* **2021**; 2: e715-25.
- 17 24. Wang Y, Zhang L, Li Q, et al. The significant immune escape of pseudotyped SARS-CoV-2 variant
18 Omicron. *Emerg Microbes Infect* **2022**; 11(1): 1-5.
- 19 25. Mbaeyi S, Oliver SE, Collins JP, et al. The Advisory Committee on Immunization Practices' Interim
20 Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United
21 States, 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70(44): 1545-52.
- 22 26. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against Covid-
23 19 in Israel. *N Engl J Med* **2021**; 385(15): 1393-400.
- 24 27. Liu J, Chandrashekar A, Sellers D, et al. Vaccines Elicit Highly Conserved Cellular Immunity to
25 SARS-CoV-2 Omicron. *Nature* **2022**.
- 26 28. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA
27 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and
28 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -
29 VISION Network, 10 States, August 2021-January 2022. *MMWR Morb Mortal Wkly Rep* **2022**;
30 71(7): 255-63.
- 31 29. US Food & Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional
32 Vaccine Dose for Certain Immunocompromised Individuals. Available
33 at: [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised)
34 [authorizes-additional-vaccine-dose-certain-immunocompromised](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised). Accessed on: 10 Jan 2022.
- 35 30. Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters
36 induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* **2022**.

37

1 **Table 1. Characteristics of COVID-19 case patients and controls without COVID-19 enrolled in vaccine**
 2 **effectiveness analysis — 21 hospitals* in 18 US states, March–December 2021.**

Characteristic (count, %)	Overall	Controls	COVID-19 Cases
Sample Size	10078	5172	4906
Vaccinated with 2 doses[†]	4348 (43.1)	3229 (62.4)	1119 (22.8)
Vaccine Product			
Moderna	1777 (40.9)	1389 (43.0)	388 (34.7)
Pfizer-BioNTech	2571 (59.1)	1840 (57.0)	731 (65.3)
Days from second dose to onset (Amongst Vaccinated), median (IQR)	139 [84, 190]	127 [75, 182]	163 [121, 206.5]
Time from second dose to onset			
Less than 180 days	3042 (70.0)	2390 (74.0)	652 (58.3)
180 days or more	1306 (30.0)	839 (26.0)	467 (41.7)
Time Period			
Pre-Delta variant period (March-June)	2800 (27.8)	1700 (32.9)	1100 (22.4)
Delta variant period (July-December)	7278 (72.2)	3472 (67.1)	3806 (77.6)
Age in years, median (IQR)	60 [46, 70]	62 [49, 72]	57 [43, 68]
65 years or older	3837 (38.1)	2271 (43.9)	1566 (31.9)
Female	4870 (48.3)	2587 (50.0)	2283 (46.5)
Race/Ethnicity[§]			
White, non-Hispanic	5675 (56.3)	3091 (59.8)	2584 (52.7)
Black, non-Hispanic	2198 (21.8)	1111 (21.5)	1087 (22.2)
Any race, Hispanic	1589 (15.8)	681 (13.2)	908 (18.5)
All other races, non-Hispanic	457 (4.5)	222 (4.3)	235 (4.8)
Unknown	159 (1.6)	67 (1.3)	92 (1.9)
U.S. Census region[¶]			
Northeast	1537 (15.2)	749 (14.5)	786 (16.0)
South	3967 (39.4)	2050 (39.6)	1917 (39.1)
Midwest	2435 (24.2)	1230 (23.8)	1205 (24.6)
West	2141 (21.2)	1143 (22.1)	998 (20.3)
Residence in long-term care facility [missing 341] **	421 (4.3)	282 (5.6)	139 (2.9)
Employed [missing 1786]	2804 (33.8)	1123 (25.7)	1681 (42.9)
Health care worker	388 (4.7)	178 (4.1)	210 (5.4)
Attended some college or more [missing 3049]	3585 (51.0)	1983 (52.1)	1602 (49.7)
≥1 hospital admission in past year [missing 757]	3904 (41.9)	2643 (55.0)	1261 (27.9)
Self-reported prior laboratory-confirmed SARS-CoV-2 infection [missing 1]	626 (6.2)	475 (9.2)	151 (3.1)
Number of categories of underlying			

medical conditions ^{††}			
0 categories of underlying conditions	1875 (18.6)	567 (11.0)	1308 (26.7)
≥1 category of underlying conditions	8203 (81.4)	4605 (89.0)	3598 (73.3)
Obese by body-mass index	4779 (47.7)	2103 (40.9)	2676 (55.0)
Immunosuppression Status ^{§§}			
Immunocompetent	8138 (80.8)	4011 (77.6)	4127 (84.1)
Immunocompromised	1940 (19.2)	1161 (22.4)	779 (15.9)

1 * Hospitals by region included Northeast: Baystate Medical Center (Springfield, Massachusetts), Beth
2 Israel Deaconess Medical Center (Boston, Massachusetts), Montefiore Medical Center (Bronx, New
3 York); South: Vanderbilt University Medical Center (Nashville, Tennessee), University of Miami Medical
4 Center (Miami, Florida), Emory University Medical Center (Atlanta, Georgia), Johns Hopkins Hospital
5 (Baltimore, Maryland), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina),
6 Baylor Scott & White Medical Center (Temple, Texas); Midwest: University of Iowa Hospitals and Clinics
7 (Iowa City, Iowa), University of Michigan Hospital (Ann Arbor, Michigan), Hennepin County Medical
8 Center (Minneapolis, Minnesota), Barnes-Jewish Hospital (St. Louis, Missouri), Cleveland Clinic
9 (Cleveland, Ohio), Ohio State University Wexner Medical Center (Columbus, Ohio); West: Stanford
10 University Medical Center (Stanford, California), UCLA Medical Center (Los Angeles, California),
11 UHealth University of Colorado Hospital (Aurora, Colorado), Oregon Health & Science University
12 Hospital (Portland, Oregon), Intermountain Medical Center (Murray, Utah), University of Washington
13 (Seattle, Washington).

14 † “Fully vaccinated” with mRNA COVID-19 vaccines defined as ≥14 days from dose 2.

15 § Racial and ethnic groups were reported by the patient or proxy.

16 ¶ Long-term care facility included reporting living in a nursing home, assisted living home, or
17 rehabilitation hospital or other subacute or chronic facility before the hospital admission.

18 ** Underlying medical condition categories were obtained through medical chart review by trained
19 personnel. Underlying conditions were defined as having a chronic condition within one or more of the

1 following condition categories: cardiovascular disease, neurologic disease, pulmonary disease,
2 gastrointestinal disease, endocrine disease, renal disease, and hematologic disease.

3 ^{††} Immunocompromising conditions included having one or more of the following: active solid organ
4 cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6
5 months), active hematologic cancer (such as leukemia, lymphoma, or myeloma), HIV infection without
6 AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ
7 transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis,
8 psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.

9

ACCEPTED MANUSCRIPT

1 **Figure 1. Adjusted vaccine effectiveness* against COVID-19 among hospitalized adults, by subgroup^{†,§}**
2 **and time interval between vaccination and illness onset**

3 *Adjusted Vaccine effectiveness (VE) was estimated using logistic regression comparing odds of case vs
4 a control outcome by a primary predictor of vaccination status (vaccinated less than 180 days before
5 symptom onset, vaccinated 180 days or more since symptom onset, or unvaccinated), using the
6 equation $VE = 100 \times (1 - \text{odds ratio})$. All models adjusted for additional covariates of date of hospital
7 admission (biweekly intervals), US Department of Health and Human Services region of hospital, age
8 (continuous), sex, and race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic of any race, non-
9 Hispanic Other, or unknown), and number of condition categories (0 vs 1 or more underlying
10 conditions). All models excluded immunocompromised individuals except for that comparing VE of
11 immunocompetent and immunocompromised individuals. The model of VE for those with no underlying
12 conditions and those with underlying conditions included an interaction term between underlying
13 conditions and vaccination status. Similarly, each model of VE for Pfizer-BioNTech vs Moderna, 18–64-
14 year-olds vs those aged 65 and older, and immunocompetent vs immunocompromised individuals each
15 included an additional covariate for vaccine product, age group, and immunosuppression status
16 respectively as well as an interaction between this factor and vaccination status. VE for delta period was
17 restricted only to patients with reference dates on or after July 1st, 2021, representing a period of
18 primarily Delta-variant. Error bars represent 95% confidence intervals.

19 [†] Immunocompromising conditions included having one or more of the following: active solid organ
20 cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6
21 months), active hematologic cancer (such as leukemia, lymphoma, or myeloma), HIV infection without
22 AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ
23 transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis,
24 psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.

1 [§] Underlying conditions were defined as having a chronic condition within one or more of the following
2 condition categories: cardiovascular disease, neurologic disease, pulmonary disease, gastrointestinal
3 disease, endocrine disease, renal disease, and hematologic disease.

4
5
6 **Figure 2. Vaccine effectiveness* against COVID-19 by time since vaccination[†] and histogram of counts**
7 **of vaccinated cases and controls by time since vaccination in immunocompetent participants**

8 * Adjusted Vaccine Effectiveness was calculated at each time since vaccination t as $VE(t) = (1 -$
9 $aOR(t)) \times 100$ where $aOR(t)$ is the estimated odds ratio of being a case patient for vaccinated
10 patients at t days since vaccination compared to an unvaccinated patient at 0 days adjusted for the
11 specified covariates. The model was adjusted for additional covariates of date of hospital admission
12 (biweekly intervals), US Department of Health and Human Services region of hospital, age (continuous),
13 sex, and race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic of any race, non-Hispanic
14 Other, or unknown), and number of condition categories (0 vs 1 or more underlying conditions).
15 Immunocompromised individuals were excluded from this model. Dotted lines represent 95%
16 confidence intervals.

17 [†] Time since vaccination is calculated as time between reference date (date of illness onset or five days
18 before hospital admission date for syndrome negative group) and date of second vaccine dose.
19 Unvaccinated individuals were given a time since vaccination of 0 days.

20
21
22
23

1 **Figure 3. Vaccine effectiveness* against COVID-19 by time since vaccination and vaccine product.**
2 **Histogram of counts of vaccinated cases and controls by time since vaccination in immunocompetent**
3 **participants**

4 * Adjusted Vaccine Effectiveness was calculated using a similar logistic regression model to the overall
5 model, with additional interaction terms for vaccine product by vaccine status and time since
6 vaccination. Immunocompromised individuals were excluded from this model. Dotted lines represent
7 95% confidence intervals.

8
9

10 **Figure 4. Vaccine effectiveness* against COVID-19 by time since vaccination[†] and age group. Histogram**
11 **of counts of vaccinated cases and controls by time since vaccination in immunocompetent**
12 **participants**

13 * Adjusted Vaccine Effectiveness was calculated using a similar logistic regression model to the overall
14 model, with additional interaction terms for age group by vaccine status and time since vaccination.
15 Immunocompromised individuals were excluded from this model. Dotted lines represent 95%
16 confidence intervals.

17




Figure 1
165x83 mm (.37 x DPI)




Figure 2
165x83 mm (.37 x DPI)

1
2
3
4
5
6
7
8
9
10





Figure 3
165x83 mm (.37 x DPI)





Figure 4
165x83 mm (.37 x DPI)

1
2
3
4
5

6
7
8